Latest & greatest articles for stroke

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on stroke or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on stroke and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for stroke

2401. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. (PubMed)

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. The Canadian American Ticlopidine Study (CATS) is a randomised, double-blind, placebo-controlled trial to assess the effect of ticlopidine (250 mg twice daily) in reducing the rate of subsequent occurrence of stroke, myocardial infarction, or vascular death in patients who have had a recent thromboembolic stroke. Twenty-five centres entered 1072 patients into the study between 1 week and 4 months after their qualifying (...) stroke. The patients were treated and followed for up to 3 years (mean 24 months). In the efficacy analysis, the event rate per year for stroke, myocardial infarction or vascular death, considered together, was 15.3% in the placebo group and 10.8% in the ticlopidine group, representing a relative risk reduction with ticlopidine of 30.2% (95% confidence interval 7.5-48.3%; p = 0.006). Ticlopidine was beneficial for both men and women (relative risk reductions 28.1%, p = 0.037, and 34.2%, p = 0.045

1989 Lancet Controlled trial quality: predicted high

2402. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. (PubMed)

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death. The medications were randomly assigned to 3069 patients with recent transient or mild (...) persistent focal cerebral or retinal ischemia. Follow-up lasted for two to six years. The three-year event rate for nonfatal stroke or death from any cause was 17 percent for ticlopidine and 19 percent for aspirin--a 12 percent risk reduction (95 percent confidence interval, -2 to 26 percent) with ticlopidine (P = 0.048 for cumulative Kaplan-Meier estimates). The rates of fatal and nonfatal stroke at three years were 10 percent for ticlopidine and 13 percent for aspirin--a 21 percent risk reduction (95

1989 NEJM Controlled trial quality: predicted high

2403. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention?

Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Malcolm L A, Kawachi I, Jackson R, Bonita R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) .) 1) Side effects of therapy are discussed but not included. 2) The costing methodology based on macro usage of health resources is of uncertain accuracy. 3) The paper makes a deliberately optimistic appraisal of therapy, in addition the type of model used is likely to be inaccurate, assuming a constant cost/benefit stream. Bibliographic details Malcolm L A, Kawachi I, Jackson R, Bonita R. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? New

1988 NHS Economic Evaluation Database.

2404. Haemodilution in acute stroke: results of the Italian haemodilution trial. Italian Acute Stroke Study Group. (PubMed)

Haemodilution in acute stroke: results of the Italian haemodilution trial. Italian Acute Stroke Study Group. In a multicentre clinical trial 1267 patients with hemispheric stroke of duration 12 h or less and haematocrit of 35% or more were prospectively randomised to either haemodilution (by venesection and replacement of the same volume of dextran 40 in saline solution) or control treatment groups. In the haemodiluted group mean haematocrit declined from 43% to 37% at 48 h and this fall (...) was maintained for seven days. A plain computed tomographic scan was obtained in all but 37 patients. 87% of the strokes were infarcts and 13% were haemorrhages. After six months the numbers of dead or severely disabled patients were equally distributed in the two treatment groups, and this was true also within the ischaemic and haemorrhagic subgroups. Furthermore, haemodilution did not improve outcome either in the group with very recent ischaemic stroke (less than 6 h) or in the subgroup with highest

1988 Lancet Controlled trial quality: uncertain

2405. A controlled trial of nimodipine in acute ischemic stroke. (PubMed)

A controlled trial of nimodipine in acute ischemic stroke. Recent investigations suggest that increased cellular calcium concentrations may be implicated in neuronal death after ischemia. To determine whether treatment with a calcium-channel blocker would improve survival and neurologic outcome in acute ischemic stroke, we enrolled 186 patients in a prospective, double-blind, randomized, placebo-controlled trial of nimodipine (30 mg every six hours), begun within 24 hours of the onset (...) of symptoms of an acute ischemic stroke. During the four-week treatment period, mortality from all causes was significantly reduced with nimodipine as compared with placebo (8 deaths [8.6 percent] vs. 19 [20.4 percent]). The improvement in survival was restricted to men. During the follow-up period of six months, an additional eight patients in each group died. A significantly better neurologic outcome, as assessed by the Mathew scale of neurologic deficit, was also observed in the nimodipine group

1988 NEJM Controlled trial quality: predicted high

2406. The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. (PubMed)

The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. In a multicentre double-blind trial, 2500 patients with a clinical diagnosis of a recent cerebrovascular event of atherothrombotic origin (transient ischaemic attack, reversible ischaemic neurological deficit, or stroke) were randomised to receive either dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP-ASA, 1250 patients) or placebo (1250 patients) thrice daily. Follow-up was twenty-four months (...) . On intention-to-treat analysis, 473 patients reached an end-point (stroke or death from any cause), 190 on DP-ASA and 283 on placebo. Survival curves for end-points showed 33% benefit in favour of the DP-ASA group (p less than 0.001). 108 patients died in the DP-ASA group and 156 in the placebo group (p less than 0.01). Results of an explanatory analysis were similar.

1987 Lancet Controlled trial quality: predicted high

2407. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. (PubMed)

Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. In a double-blind, randomised trial Org 10172 low-molecular-weight (LMW) heparinoid was compared with placebo in the prevention of deep-vein thrombosis in patients with acute thrombotic stroke. Prophylaxis was started within 7 days of the onset of stroke with a loading dose of 1000 anti-factor-Xa units intravenously followed by a fixed dose of 750 anti-factor-Xa

1987 Lancet Controlled trial quality: predicted high

2408. Double-blind randomised trial of intravenous glycerol in acute stroke. (PubMed)

Double-blind randomised trial of intravenous glycerol in acute stroke. The effects of intravenous glycerol in elderly patients with recent onset of acute ischaemic stroke were evaluated in a double-blind randomised controlled trial. 173 patients received either 500 ml of a 10% solution of glycerol in physiological saline or 500 ml of physiological saline administered intravenously over 4 h daily for 6 consecutive days. The number of deaths within the first week was 10 (12%) in the glycerol

1987 Lancet Controlled trial quality: predicted high

2409. Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? (PubMed)

Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that also assessed the value of other treatments that are simpler (...) and applicable to all stroke patients. A trial that assessed the value of aspirin and beta-blockers against control in all stroke patients would not cost much more than one restricted to comparing anticoagulants against control in patients with stroke and atrial fibrillation but would provide information of more relevance to the management of patients with stroke in the UK.

1986 Lancet

2410. Controlled trial of a home-care service for acute stroke patients. (PubMed)

Controlled trial of a home-care service for acute stroke patients. In a controlled trial of a home-care service available for the first 6 months after acute stroke, 440 patients received the new service and 417 patients were in the control group. The trial group used more hospital bed days, had a slightly higher admission rate, and did not show better emotional adjustment to stroke than the control group. There was no difference between the 2 groups in stress on relatives. Functional recovery

1985 Lancet

2411. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. (PubMed)

Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. To determine whether bypass surgery would benefit patients with symptomatic atherosclerotic disease of the internal carotid artery, we studied 1377 patients with recent hemisphere strokes, retinal infarction, or transient ischemic attacks who had atherosclerotic narrowing or occlusion of the ipsilateral internal carotid or middle (...) cerebral artery. Of these, 714 were randomly assigned to the best medical care, and 663 to the same regimen with the addition of bypass surgery joining the superficial temporal artery and the middle cerebral artery. The patients were followed for an average of 55.8 months. Thirty-day surgical mortality and major stroke morbidity rates were 0.6 and 2.5 per cent, respectively. The postoperative bypass patency rate was 96 per cent. Nonfatal and fatal stroke occurred both more frequently and earlier

1985 NEJM Controlled trial quality: uncertain

2412. Nortriptyline treatment of post-stroke depression: a double-blind study. (PubMed)

Nortriptyline treatment of post-stroke depression: a double-blind study. The efficacy of nortriptyline in the treatment of post-stroke depression was assessed by a double-blind study in thirty-four patients. Half of the patients had major depression. There was a significantly greater improvement in depression in patients treated with nortriptyline than in a similar group of placebo-treated patients. Depression was measured by the Hamilton depression scale, Zung depression scale, present state (...) examination, and an overall depression scale. Successfully treated patients had serum nortriptyline levels in the therapeutic range. Post-stroke depressions are common, severe, and longstanding, and the demonstrated efficacy of nortriptyline provides an important addition to the treatments available for stroke patients.

1984 Lancet Controlled trial quality: uncertain

2413. Effectiveness of speech therapy for aphasic stroke patients. A randomised controlled trial. (PubMed)

Effectiveness of speech therapy for aphasic stroke patients. A randomised controlled trial. Aphasic stroke patients were randomly allocated to either a speech therapy group receiving treatment twice a week for 24 weeks or a no-treatment control group. Patients in both groups improved and there were no significant differences in language recovery between the 104 patients allocated to the treatment group and the 87 allocated to the no-treatment group. This treatment regimen, which (...) is representative of clinical practice, is ineffective for most aphasic stroke patients.

1984 Lancet Controlled trial quality: uncertain

2414. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. (PubMed)

A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. Five hundred and eighty-five patients with threatened stroke were followed in a randomized clinical trial for an average of 26 months to determine whether aspirin or sulfinpyrazone, singly or in combination, influence the subsequent occurrence of continuing transient ischemic attacks, stroke or death. Eighty-five subjects went on to stroke, and 42 died. Aspirin reduced the risk (...) of continuing ischemic attacks, stroke or death by 19 per cent (P less than 0.05) and also reduced risk for the "harder," more important events of stroke or death by 31 percent (P less than 0.05), but this effect was sex-dependent: among men, the risk reduction for stroke or death was 48 per cent (P less than 0.005), whereas no significant trend was observed among women. For sulfinpyrazone, no risk reduction of ischemic attacks was observed, and the 10 per cent risk reduction of stroke or death

1978 NEJM Controlled trial quality: uncertain

2415. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. (PubMed)

Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. A trial of subcutaneous low-dose heparin in the prevention of deep-vein thrombosis was carried out in elderly patients admitted to hospital after an acute stroke. A statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning.

1977 Lancet Controlled trial quality: uncertain

2416. Double-blind trial of glycerol therapy in early stroke. (PubMed)

Double-blind trial of glycerol therapy in early stroke. The effects of intravenous glycerol and intravenous dextrose were compared using a double-blind trial in twenty-seven patients with acute stroke. Administration continued for up to 6 days. A standard scoring system was used for neurological evaluation. There was no difference in mortality or in improvement in neurological score between the two groups.

1976 Lancet

2417. Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. (PubMed)

Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. 4599980 1974 08 30 2016 10 17 0098-7484 229 4 1974 Jul 22 JAMA JAMA Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. 409-18 eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Antihypertensive Agents 0 Placebos AIM IM Adult African Continental Ancestry Group Aged Antihypertensive Agents

1974 JAMA Controlled trial quality: uncertain

2418. Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemic stroke. (PubMed)

Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemic stroke. 4678681 1973 03 05 2016 11 22 0098-7484 222 3 1972 Oct 16 JAMA JAMA Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemic stroke. 285-9 Heyman A A Fields W S WS Keating R D RD eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 AIM IM Adult African Continental Ancestry Group

1973 JAMA Controlled trial quality: uncertain

2419. Treatment of acute stroke with dextran 40. (PubMed)

Treatment of acute stroke with dextran 40. 5394364 1969 11 26 2016 11 22 0098-7484 210 2 1969 Oct 13 JAMA JAMA Treatment of acute stroke with dextran 40. 293-8 Gilroy J J Barnhart M I MI Meyer J S JS eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Carbon Isotopes 0 Dextrans AIM IM Blood Platelets cytology drug effects Blood Viscosity drug effects Carbon Isotopes Cerebrovascular Disorders drug therapy Dextrans therapeutic use Humans

1969 JAMA Controlled trial quality: uncertain